Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Rhea-AI Summary

Biodesix (Nasdaq:BDSX) will present new real-world clinical and economic data on its Nodify Lung blood-based testing strategy at the American Thoracic Society 2026 meeting in Orlando, May 15–20, 2026.

Multiple oral and poster sessions highlight lung nodule risk stratification, diagnostic lead time, and stage shift in community hospitals.

News Market Reaction – BDSX

+5.16%

3 alerts

+5.16% Session close to close

-7.0% Trough Tracked

$165.88M Market Cap

1.0x Rel. Volume

In the May 11 session, BDSX gained 5.16%, reflecting a notable positive market reaction. Argus tracked a trough of -7.0% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.2% in the session following this news. A strong positive reaction aligns with Bio...

Analysis

The stock moved +5.2% in the session following this news. A strong positive reaction aligns with Biodesix’s pattern of outsized moves on data-rich catalysts, as seen with the Q1 2026 earnings jump of 32.56%. These ATS 2026 presentations extend prior Nodify Lung® validation work and reinforce real-world use in community and academic centers. However, past declines of 6.53% and 8.74% after favorable recognition and clinical news highlight that enthusiasm has varied, and follow-through often depended on subsequent financial execution.

Key Figures

ATS 2026 dates: May 15–20, 2026 Oral presentation time: 9:27 AM Poster board P421: #P421 +5 more

8 metrics

ATS 2026 dates May 15–20, 2026 American Thoracic Society Annual Meeting schedule

Oral presentation time 9:27 AM Impact of prior cancer history oral presentation on May 17, 2026

Poster board P421 #P421 Real-world community experience using Nodify classifiers

Poster board P426 #P426 Combined Lung Cancer Identification Program stage at diagnosis study

Poster board 614 614 Mathematical modeling of tumor-associated autoantibody emergence

Poster board 313 313 PET vs biomarkers Monte Carlo simulation study

Poster board P993 #P993 Stage shift after CLIP implementation in community hospital

Exhibit booth Booth #1327 Biodesix presence on ATS exhibit floor

Historical Context

5 past events · Latest: May 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 04	Q1 2026 earnings	Positive	+32.6%	Strong revenue growth, improved losses, and raised 2026 revenue guidance.
Apr 20	Earnings date notice	Neutral	+0.2%	Announcement of Q1 2026 report date and related conference call details.
Apr 09	Workplace award	Positive	-6.5%	Third consecutive USA TODAY Top Workplaces recognition for employee engagement.
Apr 06	AACR presentations	Positive	+1.9%	AACR 2026 abstracts on novel diagnostic discovery and MRD pipeline development.
Mar 20	Clinical validation	Positive	-8.7%	Largest lung nodule biomarker validation study supporting earlier diagnosis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

BDSX has recently seen strong positive reactions to earnings, but mixed-to-negative reactions around non-financial news, including clinical and recognition updates.

Recent Company History

Over the last few months, Biodesix has combined strong financial progress with expanding clinical and scientific visibility. On Mar 20, it highlighted the largest lung nodule biomarker validation study, yet the stock fell 8.74%. Subsequent scientific conference news on Apr 6 around AACR 2026 drew a modest 1.92% gain. Corporate culture recognition on Apr 9 saw a 6.53% decline. In contrast, Q1 2026 earnings on May 4 with raised guidance produced a strong 32.56% rise, underscoring investors’ focus on financial performance over softer or scientific milestones.

Key Terms

radiomics, autoantibody, lung adenocarcinoma, pulmonary nodules, +4 more

8 terms

radiomics medical

"Biodesix Head of Radiomics, Michael Kammer, PhD, oral presentation..."

Radiomics is a method that extracts large amounts of quantitative data from medical images (like CT, MRI or PET scans) and turns visual patterns into measurable numbers, similar to reading a barcode from a photo. For investors, it matters because these data-driven signatures can improve disease detection, predict treatment response, and speed decision-making for drug development or medical devices, potentially changing clinical adoption and commercial value.

autoantibody medical

"Mathematical Modeling of a Tumor-Associated Autoantibody Emergence and Persistence..."

An autoantibody is a protein made by the immune system that mistakenly targets a person’s own cells or proteins, like a security guard that starts attacking the building it’s meant to protect. For investors, autoantibodies matter because they can be used as diagnostic markers, indicate safety issues for drugs, influence clinical trial outcomes and regulatory decisions, and therefore affect the market value of diagnostics and therapeutics companies.

lung adenocarcinoma medical

"Emergence and Persistence in Lung Adenocarcinoma: Insights Into Diagnostic Lead Time"

A common type of lung cancer that starts in the cells that line the air sacs and small airways; think of it as a patch of lung tissue that begins growing abnormally and can interfere with breathing. It matters to investors because its prevalence, available treatments, and outcomes drive demand for diagnostics, drugs and medical devices, influence regulatory approvals and clinical trial results, and can significantly affect the revenue and valuation of healthcare companies.

pulmonary nodules medical

"Risk Stratification of Indeterminate Pulmonary Nodules: Insights From Monte Carlo Simulations"

Pulmonary nodules are small, round or oval spots found in the lungs on X-rays or CT scans; they can be scar tissue, infections, or early tumors. For investors, these findings matter because they can trigger diagnostic follow-up, treatment decisions, drug or device demand, clinical trial activity, regulatory scrutiny, and potential changes in healthcare costs or company valuations—think of a nodule like a small warning light that may or may not signal a serious engine problem.

biomarkers medical

"Should We Start With PET or Biomarkers for Risk Stratification..."

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

monte carlo simulations technical

"Insights From Monte Carlo Simulations, includes authors Gerard Silvestri..."

Monte Carlo simulations use repeated random sampling to model many possible outcomes of an uncertain process, like running thousands of computerized coin- and dice-roll experiments to trace different paths for prices, interest rates, or project returns. Investors use them to estimate the probability of gains or losses, stress-test portfolios under a wide range of scenarios, and turn uncertainty into measurable ranges and odds rather than a single guess.

pet medical

"Should We Start With PET or Biomarkers for Risk Stratification..."

Positron emission tomography (PET) is a medical imaging test that creates a live map of how organs and tissues are working by tracking a tiny, safe amount of radioactive tracer inside the body. For investors, PET matters because it’s often used in clinical trials and diagnosis to show whether a drug or treatment is affecting disease — think of it as a performance meter that can speed regulatory decisions, change market forecasts, and affect a product’s commercial value.

autoantibody test medical

"Impact of Prior Cancer History on a Blood-based Autoantibody Test for Lung Nodule Risk Assessment"

A blood or tissue assay that detects antibodies the immune system mistakenly makes against the body’s own cells or proteins, used to diagnose and monitor autoimmune conditions. For investors, results and demand for these tests signal clinical need, influence sales of diagnostics and related therapies, and can affect clinical trial enrollment and regulatory decisions—similar to a warning light that guides treatment choices and market opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals

LOUISVILLE, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that additional real-world clinical and economic data related to Nodify Lung^® testing will be shared at the American Thoracic Society (ATS) Annual Meeting, May 15 – 20, 2026 | Orlando, FL. The presentations further reinforce the accelerating adoption of Biodesix blood-based testing for earlier detection of lung cancer.

“The presentations at ATS highlight the real-world clinical value and economic advantages of lung nodule management programs that use Nodify Lung^® testing for risk stratification,” said Scott Hutton, CEO of Biodesix. “It is encouraging to see major academic medical centers and community hospitals leveraging our lung diagnostic tests to expand access, educate patients, and measurably improve care and outcomes.”

Here is a quick reference list of the compelling evidence and case studies at ATS 2026:

May 17, 2026

• 9:27AM | Biodesix Head of Radiomics, Michael Kammer, PhD, oral presentation, Impact of Prior Cancer History on a Blood-based Autoantibody Test for Lung Nodule Risk Assessment"
  
  

May 18, 2026

• 11:30AM |  (Poster Board #P421) Real-world Community Experience Using Blood-Based Nodify Classifiers (CDT and XL2) For Lung Nodule Risk Stratification, authors are Roshen Mathew, MD DAABIP & Team, WVU Medicine | Camden Clark Medical Center
• 11:30AM |  (Poster Board #P426) Impact of a Combined Lung Cancer Identification Program (CLIP) on Stage at Diagnosis of Lung Cancer, 2022-2023 in a U.S. Community Hospital, authors are Maurice Smith, MD FACS & Team, Frederick Health Hospital
• 2:15PM |  (Poster Board #614) Mathematical Modeling of a Tumor-Associated Autoantibody Emergence and Persistence in Lung Adenocarcinoma: Insights Into Diagnostic Lead Time
  
  

May 19, 2026

• 9:15 AM | (Poster Board #313) Should We Start With PET or Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules: Insights From Monte Carlo Simulations, includes authors Gerard Silvestri, MD MS, Medical University South Carolina and Fabien Maldonado, MD MSc, Vanderbilt University Medical Center
• 11:30 AM | (Poster Board #P993) Stage Shift Following Implementation of the Combined Lung Cancer Identification Program (CLIP) in a U.S. Community Hospital, authors are Maurice Smith, MD FACS & Team, Frederick Health Hospital
  
  

ATS attendees can find Biodesix on the exhibit floor, Booth #1327. The full abstracts for Biodesix posters and a list of all abstracts being presented at the ATS Annual Meeting can be found here.

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung^® Nodule Risk Assessment and IQLung^® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843

FAQ

What is Biodesix (Nasdaq:BDSX) presenting at ATS 2026 about Nodify Lung testing?

Biodesix is presenting real-world clinical and economic data on its Nodify Lung blood-based testing strategy. According to Biodesix, these data demonstrate how Nodify Lung supports lung nodule risk stratification, earlier lung cancer detection, and healthcare system value in both academic and community hospital settings.

When and where will Biodesix share Nodify Lung data at the ATS 2026 meeting?

Biodesix will share Nodify Lung data at the American Thoracic Society Annual Meeting in Orlando, Florida, from May 15–20, 2026. According to Biodesix, presentations occur across multiple days, including oral and poster sessions featuring clinical outcomes and economic analyses of lung nodule management.

How does Nodify Lung testing support lung nodule risk stratification according to Biodesix?

Nodify Lung testing supports lung nodule risk stratification using blood-based classifiers to guide management decisions. According to Biodesix, presented studies examine real-world community experience, prior cancer history effects, and comparisons of PET imaging versus biomarker strategies for assessing indeterminate pulmonary nodules.

What real-world clinical evidence on Nodify Lung will be highlighted for BDSX investors at ATS 2026?

Biodesix will highlight real-world evidence from academic centers and community hospitals using Nodify Lung-based programs. According to Biodesix, these include data on stage shift after implementing the Combined Lung Cancer Identification Program and measurable improvements in access, patient education, and care pathways.

Which key Nodify Lung-related presentations featuring Biodesix will occur on May 18, 2026 at ATS?

On May 18, 2026, Biodesix-related posters cover community use of Nodify classifiers, a combined lung cancer identification program, and mathematical modeling of tumor-associated autoantibody emergence. According to Biodesix, these analyses offer insights into lung nodule risk, diagnosis stage, and diagnostic lead time.

Where can ATS 2026 attendees find Biodesix and its Nodify Lung information on-site?

ATS 2026 attendees can visit Biodesix on the exhibit floor at Booth #1327. According to Biodesix, full abstracts for its posters and a list of all related abstracts presented at the meeting are also available through the official ATS Annual Meeting abstract resources.